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  Bone	  marrow-­‐derived	  mesenchymal	  stem	  cells	  (BM-­‐MSC)	  are	  considered	  as	  a	  potential	  therapeutic	  tool	  in	  neurodegenerative	  diseases,	  due	  to	  their	  ability	  to	  migrate	  to	  degenerated	  tissues	  and	  the	  production	  of	  growth	  factors.	  Congenital	  hydrocephalus	  is	  a	  disorder	  characterized	  by	  a	  degeneration	  of	  the	  periventricular	  cerebral	  parenchyma	  and	  the	  white	  matter.	  In	  the	  present	  study,	  using	  an	  animal	  model	  of	  congenital	  hydrocephalus,	  the	  hyh	  mouse,	  it	  has	  been	  studied	  the	  capacity	  of	  the	  BM-­‐MSC	  to	  reach	  the	  degenerated	  regions	  exhibiting	  glial	  reactions	  and	  their	  probable	  neuroprotector	  effects.	  	  	  	  	  The	  BM-­‐MSC	  were	  isolated	  from	  two	  sources:	  a)	  transgenic	  mice	  expressing	  the	  monomeric	  red	  fluorescent	  protein	  (mRFP1);	  b)	  wild	  type	  mice.	  In	  the	  second	  case,	  the	  BM-­‐MSC	  were	  labelled	  in	  vitro	  using	  bromodeoxyuridine,	  a	  fluorescent	  cell	  tracker	  and	  the	  lipophilic	  DiR.	  	  Before	  application,	  the	  cells	  were	  analysed	  using	  flow	  cytometry	  and	  immunofluorescence.	  The	  BM-­‐MSC	  were	  injected	  into	  the	  retro-­‐orbital	  sinus	  or	  into	  the	  lateral	  ventricle	  of	  hyh	  mice.	  After	  24/96	  hours	  of	  administration,	  they	  were	  detected	  under	  light,	  confocal	  and	  electron	  microscopes.	  The	  injected	  BM-­‐MSC	  reached	  the	  degenerated	  periventricular	  regions	  and	  the	  disrupted	  neurogenic	  niches.	  They	  were	  detected	  in	  the	  periventricular	  parenchyma,	  around	  periventricular	  blood	  vessels	  and	  in	  the	  ventral	  meninges.	  Most	  of	  the	  applied	  BM-­‐MSC	  expressed	  the	  glial	  cell-­‐derived	  neurotrophic	  factor	  (GDNF),	  in	  the	  same	  way	  as	  the	  periventricular	  reactive	  astrocytes,	  suggesting	  a	  possible	  neuroprotector	  effect.	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